| Literature DB >> 35392943 |
Emma Chew Murphy1, Antoinette Danvers1, Andrés Ramírez Zamudio2, Karina Avila1, Meghan Proehl2, Tatiana Gonzalez-Argoti3, Joanne E Mantell4, Laurie J Bauman3, Siobhan M Dolan5,6.
Abstract
BACKGROUND: Use of HIV PrEP (pre-exposure prophylaxis) is a strategic tool in the effort to end the HIV epidemic. 20% of new HIV infections in the US are among cis-gender women, yet they comprise only 5% of all PrEP users. Black women disproportionately bear the burden of new HIV acquisition and accounted for almost 60% of new HIV diagnoses among women in 2018. Increasing understanding and uptake of PrEP among women at risk of HIV acquisition in alignment with their reproductive values and preferences is key to increasing PrEP uptake and decreasing HIV burden in this population.Entities:
Keywords: Birth control; HIV prevention; PrEP; Sex positivity; Sexual health
Mesh:
Substances:
Year: 2022 PMID: 35392943 PMCID: PMC8991476 DOI: 10.1186/s12978-022-01393-y
Source DB: PubMed Journal: Reprod Health ISSN: 1742-4755 Impact factor: 3.223
Characteristics of the participants interviewed in the study
| Characteristics | N (%) | Mean (S.D.)[Range] |
|---|---|---|
| Age | 30 | 29.73 (5.36)[20–41] |
| Race/ethnicity | ||
| Latinx | 18 (60%) | |
| Black/African American | 10 (33%) | |
| Other | 2 (7%) | |
| Sexual orientation | ||
| Heterosexual | 25 (83%) | |
| Bisexual | 5 (27%) | |
| Relationship status | ||
| Married | 8 (27%) | |
| Single, never married | 20 (67%) | |
| Domestic partnership | 2 (7%) | |
| Education | ||
| < High school | 4 (13%) | |
| High school/GED/Vocational training | 6 (20%) | |
| Some college | 13 (43%) | |
| Associate degree or higher | 7 (23%) | |
| Number of sexual partners in the last year | 1.83 (1.44)[1–6] | |
| 1–2 partners | 23 (77%) | |
| 3 or more partners | 7 (23%) | |
| Sexually transmitted infection (STI) in the last year | ||
| No | 24 (80%) | |
| Yes | 6 (20%) | |
| Number of live births among women who have ever been pregnant pregnant (n = 29) | ||
| 0 live births | 8 (28%) | |
| > 1 live birth | 21 (70%) | |
| HIV testing history | ||
| Ever tested | 29 (97%) | |
| Never tested | 1 (3%) | |
| Positive screen for HIV acquisition risk | ||
| Yes | 21 (70%) | |
| No | 9 (30%) | |
| Learned about PrEP from a medical professional | ||
| Yes | 4 (13%) | |
| No | 25 (83%) | |
| Not sure | 1 (33%) | |
| Ever been prescribed PrEPs | ||
| Yes | 0 (0%) | |
| No | 30 (100%) |
Current contraceptive use of the participants interviewed in the study
| Current contraceptive use among those who do not desire pregnancy (n = 15) | N (%) |
|---|---|
| Condoms exclusively | 2 (13%) |
| Birth control pills | 4 (27%) |
| Depo-Provera | 3 (20%) |
| Contraceptive implant | 2 (13%) |
| Vaginal Ring | 1 (7%) |
| IUD | 3 (20%) |
| 2 or more methods | 4 (27%) |
| No method reported | 1 (7%) |
| Themes | Subthemes | Codes |
|---|---|---|
| PrEP is another “daily pill for women” | PrEP is accessible for women Adherence to birth control as a gauge for PrEP adherence | Birth control and PrEP Sexual health priorities HIV/STI prevention strategies PrEP and sex life/sexual pleasure Female controlled method Transparency/disclosure of sexual health topics PrEP and stigma PrEP and adherence PrEP and covert use PrEP willingness and receptivity |
| PrEP for autonomy and pleasure in women’s sexual health | Control over method Covert method Freedom in sexual expression | |
| Multiple delivery options for PrEP | Adherence to daily pill Longer-acting formulation Injectable PrEP |